Vital

Dosing

Peptide Half-Life: How Long It Stays in Your System

What peptide half-life means, how long semaglutide and tirzepatide stay in your system, the five half-lives rule, and why the BPC-157 half-life figure comes only from animals.

Last reviewed

The Vital angle

When you open a logged dose in Vital, a "Still in your system" card shows the half-life of each compound, the percent of that dose estimated to remain, and when it is mostly gone at five half-lives. If no half-life figure exists for a compound, the card shows "Not established" instead of a number, and figures without human data carry a note that they are a rough guide only. The card is an estimate for your records, not medical advice.

What peptide half-life means

Peptide half-life is the time it takes for the amount of a compound in your blood to fall by half. It is the number people reach for when they ask how long a shot stays in their system, how long a side effect might last, or when a medication is "gone." It is a useful number, but it is easy to misread.

Most peptide drugs leave the body in a roughly predictable way called first-order elimination. The body removes a fixed fraction of what is left in each time period, not a fixed amount. That is why the curve never quite reaches zero. Each half-life removes half of what remains, so the drop is large at first and small later.

Half-life is different from how long a drug works. A medication can keep acting after blood levels fall, or stop acting while some is still circulating. It is also different from the time to peak, which is how long it takes to reach the highest level after a dose. For context on schedules, see the guide to GLP-1 dosing schedules.

The five half-lives rule

Clinicians often treat a drug as effectively cleared after about five half-lives. The arithmetic is simple, and it works the same for any compound with first-order elimination.

This is a math example with a clearly hypothetical compound, not a dose or a schedule. Suppose a compound had a half-life of exactly 1 day:

  1. After 1 day, about 50 percent of a single dose remains.
  2. After 2 days, about 25 percent remains.
  3. After 3 days, about 12.5 percent remains.
  4. After 4 days, about 6 percent remains.
  5. After 5 days, about 3 percent remains.

At five half-lives, roughly 97 percent of that single dose is gone. That is a convention, not a hard line. A small amount is still there, and the rule says nothing about how strong the effect of that small amount is.

Repeated doses change the picture. With regular dosing, levels build until the amount removed between doses matches the amount added. That balance point is called steady state, and it also takes about four to five half-lives to reach. When you stop, the five half-lives count starts from the last dose, not the first.

How long semaglutide stays in your system

Semaglutide is the active ingredient in Wegovy® and Ozempic®. The FDA label for Wegovy gives an elimination half-life of about one week. The label states that semaglutide will be present in the circulation for about five to seven weeks after the last injectable dose. That range lines up with the five half-lives rule.

The same long half-life explains a few label details. The Wegovy label advises stopping at least two months before a planned pregnancy because of the long half-life of semaglutide. It is also why a missed weekly dose does not drop levels to zero in a few days. For what to do after a missed injection, read the missed GLP-1 dose guide and follow the instructions in your own label or from your prescriber.

Tirzepatide half-life

Tirzepatide is the active ingredient in Zepbound® and Mounjaro®. The Zepbound label lists an elimination half-life of about five to six days in people with overweight or obesity, and the overdose section uses about five days. A fatty acid chain on the molecule binds to albumin in the blood, which slows its removal.

Using the five half-lives rule as a rough guide, most of a single tirzepatide dose is gone in about four weeks. The label itself does not set a washout period. If you are moving between medications, the semaglutide to tirzepatide switching guide explains why a prescriber, not the half-life alone, sets the timing.

BPC-157 half-life evidence

BPC-157 is not an FDA-approved drug. The half-life figure that circulates online comes from one study in rats and beagle dogs, published in 2022. In that study, the elimination half-life of the intact peptide was under 30 minutes in both species, and about 15 minutes in rats after an intravenous injection. The intact peptide was not detectable in rats four hours after the dose.

That study does not tell you the half-life in people. No published human pharmacokinetic study for BPC-157 was found for this guide. Animal figures can differ from human figures, and the study measured only the intact peptide, not every fragment it breaks down into. Products sold online also vary in content and purity, so the compound in a vial may not match the one in the study.

The FDA has raised safety concerns about several peptides that compounders nominated, including BPC-157. In July 2026, an FDA advisory committee voted to recommend adding BPC-157 and several other peptides to the list of bulk substances for compounding. That vote is not binding, it is not an approval, and the FDA had not finished any rulemaking at the time of this review. The same caution applies to other research peptides with no human data. For more on this group, see peptide cycling protocols and the Wolverine stack guide.

What half-life means before surgery

Many people look up half-life before a procedure and try to count back five half-lives. Do not plan a washout from a half-life on your own. Ask your surgeon and the anesthesia team what to do, and tell them about every medication and peptide you use.

The concern before anesthesia with GLP-1 medications is mostly slow stomach emptying, which can raise the risk of inhaling stomach contents during sedation. A 2024 guidance from several medical societies, including the American Society of Anesthesiologists, says that many people at low risk can continue their GLP-1 medication before elective surgery. For people at higher risk, the team may change the diet before the procedure, change the anesthesia plan, or hold a dose. When they hold a weekly medication, the guidance timing is about one week, not five half-lives.

That difference matters. A half-life tells you about blood levels. Your surgical team decides based on your symptoms, your procedure, and the reason you take the medication. Stopping on your own can also affect blood sugar or other conditions the medication treats.

Limits of a half-life number

A half-life is an average from a study population. Several factors make your own timeline differ:

  1. Kidney or liver function can change how fast some compounds clear.
  2. The route matters. An injection under the skin, into a muscle, or into a vein can give very different curves.
  3. Repeated doses build up to steady state, so the time to clear after many doses is not the same as after one.
  4. Effects can outlast blood levels, or fade before them.
  5. For research peptides, the figure may come only from animals, a lab study, or a seller's claim.

The peptide catalog source checks guide shows how to tell a label figure from a seller figure.

When to get medical help

A half-life does not tell you when a side effect is safe to wait out. Get medical care right away for any of these signs:

  1. Severe stomach pain that does not go away, with or without vomiting, which can be a sign of pancreatitis.
  2. Pain in the upper right abdomen, fever, or yellow skin or eyes.
  3. Vomiting or diarrhea that stops you from keeping fluids down, or very little urine.
  4. Signs of low blood sugar, such as shakiness, sweating, or confusion, especially with insulin or a sulfonylurea.
  5. A hot, spreading, or very painful injection site, or a fever.

Get emergency care for swelling of the face, lips, tongue, or throat, or trouble breathing.


Wegovy®, Ozempic® are trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® are trademarks of Eli Lilly and Company. Vital is independent and not affiliated with these companies.

Free toolPeptide reconstitution calculator

Things to watch

Practical flags drawn from prescribing information and clinical guidance. Vital surfaces these in the dose log to help you spot them early.

  • Half-life figures from seller pages

    Many research peptide half-lives online come from animal studies, lab studies, or no study at all. Check whether a figure comes from an FDA label or human pharmacokinetic study before you rely on it.

  • Counting five half-lives to plan surgery

    Pre-anesthesia advice for GLP-1 medications is based mainly on stomach emptying and personal risk, not on clearance math. Ask your surgeon and anesthesia team what to do.

  • BPC-157 and other unapproved peptides

    BPC-157 is not an FDA-approved drug, and its published half-life is from rats and dogs only. A July 2026 advisory committee vote on compounding is not binding and is not an approval.

  • Treating cleared as zero effect

    Five half-lives leaves about 3 percent of a single dose, and effects can outlast or fall short of blood levels. Half-life is one input, not a full picture of how a drug acts in you.

  • Single-dose math after many doses

    Regular dosing builds levels to steady state. The clearance clock starts from the last dose, and your prescriber can explain what that means for your medication.

Frequently asked questions

  • It is the time it takes for the amount of a peptide in your blood to fall by half. After each half-life, half of what remains is gone, so levels drop fast at first and slowly later.

  • The Wegovy label gives a half-life of about one week and says semaglutide stays in the circulation for about five to seven weeks after the last injectable dose.

  • The Zepbound label lists about five to six days in people with overweight or obesity. By the five half-lives rule, most of a single dose is gone in about four weeks, but the label sets no washout period.

  • After five half-lives, about 97 percent of a single dose is gone, so clinicians often treat the drug as effectively cleared. It is a convention. A small amount remains, and effects can differ from blood levels.

  • No published human pharmacokinetic study was found. A 2022 study in rats and dogs measured a half-life under 30 minutes for the intact peptide. BPC-157 is not an FDA-approved drug.

  • Do not plan this on your own. A 2024 multi-society guidance says many low-risk people can continue, and others may get a diet change, a different anesthesia plan, or a held dose. Ask your surgeon and anesthesia team.

Sources

  1. WEGOVY (semaglutide) injection and tablets: Label · DailyMed / U.S. National Library of Medicine
  2. ZEPBOUND (tirzepatide) Prescribing Information · Eli Lilly and Company
  3. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs · NIH / NCBI
  4. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period · NIH / NCBI
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
  6. FDA Panel Backs 6 Peptides for Compounding · AJMC

This page summarizes publicly available information from the sources listed above and is for educational use only. It is not medical advice. Consult a qualified healthcare professional for personal dosing guidance.

Track every shot, every change

Vital logs every GLP-1 injection and peptide dose, then surfaces patterns your scale can't show. Free on iOS and Android.